Advertisement

Topics

PubMed Journals Articles About "Biomarkers Predicting Response In Patients With Non-Small Cell Lung Cancer Previously Treated With Erlotinib Hydrochloride" RSS

09:37 EDT 14th August 2018 | BioPortfolio

Biomarkers Predicting Response In Patients With Non-Small Cell Lung Cancer Previously Treated With Erlotinib Hydrochloride PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Biomarkers Predicting Response In Patients With Non-Small Cell Lung Cancer Previously Treated With Erlotinib Hydrochloride articles that have been published worldwide.

More Information about "Biomarkers Predicting Response In Patients With Non-Small Cell Lung Cancer Previously Treated With Erlotinib Hydrochloride" on BioPortfolio

We have published hundreds of Biomarkers Predicting Response In Patients With Non-Small Cell Lung Cancer Previously Treated With Erlotinib Hydrochloride news stories on BioPortfolio along with dozens of Biomarkers Predicting Response In Patients With Non-Small Cell Lung Cancer Previously Treated With Erlotinib Hydrochloride Clinical Trials and PubMed Articles about Biomarkers Predicting Response In Patients With Non-Small Cell Lung Cancer Previously Treated With Erlotinib Hydrochloride for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Biomarkers Predicting Response In Patients With Non-Small Cell Lung Cancer Previously Treated With Erlotinib Hydrochloride Companies in our database. You can also find out about relevant Biomarkers Predicting Response In Patients With Non-Small Cell Lung Cancer Previously Treated With Erlotinib Hydrochloride Drugs and Medications on this site too.

Showing "Biomarkers Predicting Response Patients With Small Cell Lung" PubMed Articles 1–25 of 72,000+

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.

Upregulated expression and aberrant activation of the epidermal growth-factor receptor (EGFR) are found in lung cancer, making EGFR a relevant target for non-small-cell lung cancer (NSCLC). Treatment with anti-EGFR monoclonal antibodies (mAbs) is associated with modest improvement in overall survival in patients with squamous cell lung cancer (SqCLC) who have a significant unmet need for effective treatment options. While there is evidence that using EGFR gene copy number, EGFR mutation, and EGFR protein ex...


Prediction of platinum-based chemotherapy efficacy in lung cancer based on LC-MS metabolomics approach.

Lung cancer is the common cause of cancer-related death worldwide. Platinum-based chemotherapy is the cornerstone of treatment for lung cancer. Platinum sensitivity is a major possibility for effective cancer treatment. In this study, several potential biomarkers were identified for evaluating and predicting the response to platinum-based chemotherapy. LC-MS-based metabolomics was performed on plasma samples from 43 lung cancer patients with different chemotherapy efficacy. By combing multivariate statistic...

Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.

Biomarkers for predicting the effect of anti-programmed cell death 1 (PD-1) monoclonal antibody against non-small-cell lung cancer (NSCLC) are urgently required. Although it is known that the blood levels of soluble programmed cell death ligand 1 (sPD-L1) are elevated in various malignancies, the nature of sPD-L1 has not been thoroughly elucidated. We investigated the significance of plasma sPD-L1 levels as a biomarker for anti-PD-1 monoclonal antibody, nivolumab therapy.


Prognostic Impact of Tumor Mutation Burden in Patients with Completely Resected Non-Small Cell Lung Cancer: Brief Report.

Tumor mutation burden (TMB), is thought to be associated with the amount of neoantigen in the tumor and to have an important role in predicting the effect of immune checkpoint inhibitors. However, the relevance of TMB to prognosis is not yet fully understood. In this study, we investigated the clinical significance of TMB in patients with non-small cell lung cancer (NSCLC) and examined the relationship between TMB and prognosis.

Clinical impact of pretreatment prognostic nutritional index (PNI) in small cell lung cancer patients treated with platinum-based chemotherapy.

Numbers of prognostic factors of small cell lung cancer (SCLC) have been demonstrated in previous studies. However, the identification of biomarkers with easy access, convenience and low consumption is of great value in clinics.

Strong PD-L1 expression predicts poor response and de novo resistance to EGFR TKIs among non-small cell lung cancer patients with EGFR mutation.

This study evaluated whether tumor expression of programmed death-ligand 1 (PD-L1) could predict the response of EGFR-mutated non-small cell lung cancer (NSCLC) to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy.

PD-1/PD-L1 Axis in Lung Cancer.

Cancer immunotherapies have revolutionized the treatment of non-small cell lung cancer. Yet, only a small subset of patients will benefit from PD-1 or PD-L1 blockade. PD-L1 tumor cell expression is the only approved biomarker at present. Tumor mutational burden and other emerging biomarkers should improve patient selection. Combination therapy approaches with chemotherapy or cytotoxic T-lymphocyte-associated protein 4 blockade may increase the proportion of patients who benefit from immunotherapy. Although ...

Genomic Features of Response to Combination Immunotherapy in Lung Cancer.

In this issue of Cancer Cell, Hellmann et al. describe in two clinical trials the importance of tumor mutational burden as an independent predictive marker for outcomes with combination nivolumab plus ipilimumab as first-line therapy in metastatic non-small-cell lung cancer and in relapsed small-cell lung cancer.

Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents.

Anti-programmed cell death-1 (PD-1) agents enhance the antitumor immunoresponse. A number of reports have indicated that patients with malignancies who receive anti-PD-1 agents are at risk for tuberculosis (TB) infection. In this report, we present a patient with non-small cell lung cancer who developed pulmonary tuberculosis while receiving the anti-PD-1 agent nivolumab, and who subsequently demonstrated a paradoxical response (PR) 10 days after initiation of anti-MTB treatment. We suggest that anti-PD-1 a...

Knockdown of lncRNA GHET1 suppresses cell proliferation, invasion and LATS1/YAP pathway in non small cell lung cancer.

The aim in this study was to explore the role of long non-coding RNA GHET1 in development of non small cell lung cancer (NSCLC).

Candidate MicroRNA Biomarkers of Therapeutic Response to Sunitinib in Metastatic Renal Cell Carcinoma: A Validation Study in Patients with Extremely Good and Poor Response.

Targeted therapy with the tyrosine kinase inhibitor sunitinib is used in the first line of metastatic renal cell carcinoma (mRCC) treatment. The aim of the present study was independent validation of microRNAs (miRNAs) identified in previous studies as biomarkers predicting response to sunitinib therapy.

Upregulation of serum miR-494 predicts poor prognosis in non-small cell lung cancer patients.

Emerging studies show that microRNAs (miRNAs) play a essential role in tumorigenesis. Deregulation of miR-494 is frequently observed in various human cancers including non-small cell lung cancer (NSCLC). However, little is known about the clinical significance of serum miR-494. The aim of this study was to investigate the diagnostic and prognostic value of serum miR-494 for NSCLC.

Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios may aid in identifying patients with non-small cell lung cancer and predicting Tumor-Node-Metastasis stages.

The present study aimed to identify a high-risk population with non-small cell lung cancer (NSCLC) and to predict TNM stages using the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR). This retrospective study included preoperative data of 171 patients and 105 controls. Compared with healthy controls, patients with NSCLC had higher levels of NLR and PLR (NLR, 2.719±0.183 vs. 1.813±0.079, P

DOES ADVANCED LUNG INFLAMMATION INDEX (ALI) HAVE PROGNOSTIC SIGNIFICANCE IN METASTATIC NON-SMALL CELL LUNG CANCER?

Lung cancer is the most commonly diagnosed and death-related cancer type and is more frequent in males. Non-small cell lung cancer accounts for about 85%of all case. In this study it was aimed to research the relationship between advanced lung inflammation index (ALI) and the primary mass maximum standardized uptake value (SUVmax) and C-reactive protein (CRP) at initial diagnosis; and the prognostic value of ALI in determining the survival in metastatic non-small cell lung cancer (NSCLC) Methods: 112 patien...

MiR-93-5p up-regulation is involved in non-small cell lung cancer cells proliferation and migration and poor prognosis.

MicroRNA-93-5p (miR-93-5p) dysregulation has been reported in many types of human cancer. However, the collective effect of miR-93-5p in both lung adenocarcinoma and squamous cell carcinoma and the mechanism underlying miR-93-5p involvement in non-small cell lung cancer cells (NSCLC) is unknown. Herein, our purpose was to reveal the role and explain this mechanism, with the goal of contributing to the development of new diagnostic biomarkers and individualized therapeutic targets.

Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)-validation in two independent cohorts.

Effective predictive biomarkers for selection of patients benefiting from adjuvant platinum-based chemotherapy in non-small cell lung cancer (NSCLC) are needed. Based on a previously validated methodology, molecular profiles of predicted sensitivity in two patient cohorts are presented.

A Prospective Observational Study Evaluating the Correlation of c-MET Expression and EGFR Gene Mutation with Response to Erlotinib as Second-Line Treatment for Patients with Advanced/Metastatic Non-Small-Cell Lung Cancer.

We aimed to evaluate the prevalence and predictive role of c-MET expression and EGFR mutation in the efficacy of erlotinib in non-small-cell lung cancer (NSCLC).

Adjuvant chemotherapy improves survival in patients with completely resected T3N0 non-small cell lung cancer invading the chest wall.

Adjuvant chemotherapy prolongs survival in patients with non-small cell lung cancer with N1 disease or tumors larger than 4 cm. Patients with T3N0 disease due to chest wall invasion often receive adjuvant chemotherapy because their disease is classified as stage II non-small cell lung cancer. This study evaluated whether chemotherapy improves survival after complete resection of T3N0 non-small cell lung cancer with invasion of the chest wall.

Radiologic pseudoprogression during anti-PD1 therapy for advanced non-small cell lung cancer.

Anti-PD1 (programmed cell death protein 1) therapy can lead to unconventional tumor responses including radiologic pseudoprogression. Here we determine the real-world incidence of radiologic pseudoprogression in advanced non-small cell lung cancer (NSCLC) and compare radiologic response criteria for disease response assessment.

The impact of coexisting lung diseases on outcomes in patients with pathological Stage I non-small-cell lung cancer.

Cigarette smoking is a well-known cause of interstitial lung disease (ILD), pulmonary emphysema and lung cancer. Coexisting pulmonary disease can affect prognosis in patients with lung cancer. The aim of this study was to determine the influence of pulmonary disease on outcomes in patients with a smoking history who had undergone surgery for pathological Stage I non-small-cell lung cancer.

Targeted Therapy With Anaplastic Lymphoma Kinase Inhibitor (Alectinib) in Adolescent Metastatic Non-Small Cell Lung Carcinoma: 18F-NaF PET/CT in Response Evaluation.

Primary lung adenocarcinoma is extremely rare in the pediatric age group. We report an 18-year-old man with non-small cell lung carcinoma stage IV with brain and bone metastatic. Lung biopsy showed expression of PDL1 along with rearrangement of ALK gene at chromosome 2p23. However, neither mutation of ROS1 nor epidermal growth factor receptor overexpression was seen. Second-generation anaplastic lymphoma kinase (ALK) inhibitor (alectinib) is initiated as first line of treatment. After 8 months of treatment ...

Efficacy of Crizotinib Among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-small-cell Lung Cancer.

ROS1 rearrangement-positive non-small-cell lung cancer (NSCLC) can be treated effectively, with an anaplastic lymphoma kinase (ALK)/ROS1/mesenchymal-epithelial transition factor inhibitor such as crizotinib. However the rate of response remains variable. Although several ROS1 fusion partners have been identified, the efficacy of crizotinib in patients with different types of ROS1 fusion partners is poorly understood.

A Direct Plasma miRNA Assay for Early Detection and Histological Classification of Lung Cancer.

Cell-free microRNAs in plasma provide circulating biomarkers for lung cancer. Most techniques for analysis of miRNAs require a large plasma volume to purify a sufficient RNA yield followed by complicated downstream processing. Small differences in the multiple procedures often cause large analytical variations and poor diagnostic values of the plasma biomarkers. Here we investigate whether directly quantifying plasma miRNAs without RNA purification could diagnose lung cancer. FirePlex assay was directly app...

Identification of potential tumor-educated platelets RNA biomarkers in non-small-cell lung cancer by integrated bioinformatical analysis.

Platelets have emerged as key players in tumorigenesis and tumor progression. Tumor-educated platelet (TEP) RNA profile has the potential to diagnose non-small-cell lung cancer (NSCLC). The objective of this study was to identify potential TEP RNA biomarkers for the diagnosis of NSCLC and to explore the mechanisms in alternations of TEP RNA profile.

Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients with Non-Small-Cell Lung Cancer.

Despite widespread administration of programmed death receptor 1 (PD-1) pathway inhibitors among individuals with non-small-cell lung cancer (NSCLC), little is known about the safety and activity of these agents among human immunodeficiency virus (HIV) infected patients since this population has largely been excluded from immunotherapy clinical trials.


Advertisement
Quick Search
Advertisement
Advertisement